Retrospective Research on Lung Cancer Patients Receiving Neoadjuvant Immunochemotherapy From Zhongshan Hospital Fudan University.

Shanghai Zhongshan Hospital1 site in 1 country83 target enrollmentJanuary 2017

ConditionsLung Cancer

InterventionsNeoadjuvant immunochemotherapy

DrugsNeoadjuvant immunochemotherapy

Overview

Phase: Not Applicable
Intervention: Neoadjuvant immunochemotherapy
Conditions: Lung Cancer
Sponsor: Shanghai Zhongshan Hospital
Enrollment: 83
Locations: 1
Primary Endpoint: Overall survival (OS)
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

We retrospectively analyzed lung cancer patients who had NAICT and surgery in the Department of Thoracic Surgery, Zhongshan Hospital. NAICT was defined as chemotherapy that included at one application of PD-1 inhibitor.

Registry

clinicaltrials.gov

Start Date

January 2017

End Date

July 2023

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Shanghai Zhongshan Hospital

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Lung surgery was performed in the Department of Thoracic Surgery at Zhongshan Hospital;
•At least one cycle of neoadjuvant treatment containing the immune drug PD-1 immunosuppressant was performed before surgery;
•Malignancy was present and confirmed in the pathology before treatment and after surgery;
•The lung lesion was the primary lesion.

Exclusion Criteria

•No lung surgery was performed until 2022.11;
•No preoperative neoadjuvant therapy was performed or recorded;
•Neoadjuvant therapy did not include immune drugs;
•Previous history of malignancy (including surgery and adjuvant therapy);
•Previous use of system-related immune medicines, such as immunosuppressants and monoclonal antibodies; and
•Other conditions inappropriate for enrollment by the investigator.